DVAX - Dynavax Technologies Corporation
| Previous Close | 12.20 |
| Open | 12.15 |
| Bid | 12.00 x 800 |
| Ask | 12.40 x 3200 |
| Day's Range | 11.81 - 12.30 |
| 52 Week Range | 11.35 - 24.45 |
| Volume | 1,148,954 |
| Avg. Volume | 880,737 |
| Market Cap | 751.387M |
| Beta | -0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.11 |
| Earnings Date | Nov 1, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.50 |
- GlobeNewswire•19 days ago
Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
Dynavax Technologies Corporation (DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to generate durable, systemic anti-tumor immunity. The paper titled Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay, by Dynavax scientists M.Gallotta, H. Assi, E. Degagné, S. Kannan, R.Coffman and C. Guiducci was published in the journal Cancer Research.
- GlobeNewswire•26 days ago
Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
Dynavax Technologies Corporation (DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been published by Cancer Discovery, a journal publication from American Association of Cancer Research (AACR). The investigators report clinical activity and broad immune activation in the tumor microenvironment when SD-101 is administered in combination with either low dose radiation in patients with indolent lymphoma or in combination with PD-1 blockade in patients with unresectable or metastatic melanoma. “Promising data from multiple trials studying intratumoral administration of TLR9 agonists indicate that stimulating the innate immune system through the TLR9 pathway can enhance the adaptive immune response to both injected and non-injected tumors,” said Antoni Ribas, M.D., Ph.D., Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.
- Motley Fool•last month
Is Dynavax Technologies Corporation a Buy?
A slow launch for its hepatitis B vaccine has hurt Dynavax. But are better days ahead?
- Thomson Reuters StreetEvents•last month
Edited Transcript of DVAX earnings conference call or presentation 6-Aug-18 8:30pm GMT
Q2 2018 Dynavax Technologies Corp Earnings Call
- Motley Fool•last month
Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
- GlobeNewswire•last month
Consolidated Research: 2018 Summary Expectations for National Instruments, Dynavax Technologies, BWX Technologies, Fossil Group, GCP Applied Technologies, and Stratasys — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National ...
- Zacks•2 months ago
Dynavax Technologies (DVAX) Reports Q2 Loss, Lags Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -6.78% and -24.23%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Dynavax Technologies: 2Q Earnings Snapshot
On a per-share basis, the Berkeley, California-based company said it had a loss of 63 cents. The biopharmaceutical company posted revenue of $1.3 million in the period. Dynavax Technologies shares have ...
- GlobeNewswire•2 months ago
Dynavax Reports Second Quarter 2018 Financial Results
HEPLISAV-B ® Launch Progressing as Planned with Key Customer Successes. Three abstracts accepted for presentation at European Society for Medical Oncology 2018 Annual Meeting. Conference Call to be held ...
- ACCESSWIRE•2 months ago
Dynavax Technologies Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Dynavax Technologies Corporation (NASDAQ: DVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM ...
- GlobeNewswire•2 months ago
Dynavax to Host Second Quarter 2018 Financial Results Conference Call
Dynavax Technologies Corporation (DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018 after market close on Monday, August 6, 2018, and host a conference call that day to review the results and provide an update on the launch of HEPLISAV-B® [Hepatitis B Vaccine, (Recombinant) Adjuvanted] and its oncology program at 4:30pm ET/1:30pm PT. To access the call, participants must dial (800) 239-9838 in the U.S. or (323) 794-2551 internationally, and use the conference ID 2303066. The conference ID for the replay will be 2303066.
- Benzinga•2 months ago
Jim Cramer Weighs In On Barrick Gold, Childrens Place And More
Jim Cramer recommended on CNBC's "Mad Money Lightning Round" a long position in Childrens Place Inc (NASDAQ: PLCE ). He would buy the weakness in the stock. Dynavax Technologies Corporation (NASDAQ: ...
- CNBC•2 months ago
Cramer's lightning round: The best way to add gold to your portfolio
Jim Cramer rattles off his take on callers' favorite stocks, including his take on how investors should approach the gold market.
- ACCESSWIRE•2 months ago
Free Technical Research on Edge Therapeutics and Three More Biotech Equities
On Friday, July 6, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: CytomX Therapeutics Inc. (NASDAQ: CTMX), Dynavax Technologies Corp. (NASDAQ: DVAX), Edge Therapeutics Inc. (NASDAQ: EDGE), Editas Medicine Inc. (NASDAQ: EDIT).
- GlobeNewswire•3 months ago
Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
Dynavax Technologies Corporation (DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience in research, development, and commercialization in the fields of oncology and immunology.
- GlobeNewswire•3 months ago
Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B. Data Presented at 2018 American Diabetes Association Annual ...
- TheStreet.com•3 months ago
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
The huge American Society of Clinical Oncology or ASCO confab has called it a wrap for another year. Keytruda to treat PD-1-naive advanced melanoma patients. Dynavax's main asset for the time being is Heplisav-B, a hepatitis B vaccine approved by the FDA late in 2017.
- Simply Wall St.•4 months ago
What Did Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO Take Home Last Year?
Eddie Gray took the helm as Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO and grew market cap to US$993.27M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- TheStreet.com•4 months ago
4 Names to Watch Ahead of This Year's Key Cancer-Research Conference
The American Society of Clinical Oncology conference -- the biggest event of the year for oncology firms and investors -- kicks off June 1 in Chicago, and scores of firms typically release abstracts right around now of studies that they'll be presenting at the event, which is known as "ASCO." that means a myriad of oncology names have either already moved or will soon do so on these reports. It presented promising data last year around its compound larotrectinib -- news that eventually parlayed its way into a $1.5 billion collaboration deal with Bayer. This year, Loxo will report that an early stage Phase 1 trial involved a compound called LOXO-292 showed a 69% overall response rate among RET-positive patients with non-small-cell lung cancer and a type of thyroid cancer.
- Simply Wall St.•4 months ago
Should Dynavax Technologies Corporation’s (NASDAQ:DVAX) Recent Earnings Worry You?
Assessing Dynavax Technologies Corporation’s (NASDAQ:DVAX) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of DVAX earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 Dynavax Technologies Corp Earnings Call
